NGM Biopharmaceuticals Inc (OQ:NGM)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 333 Oyster Point Blvd
Tel: N/A
IR: See website
Key People
David V. Goeddel
Chairman of the Board
Marc Learned
Executive Director, Research Operations
Jeffrey D. Jonker
William J. Rieflin
Chief Executive Officer, Director
Jin-Long Chen
Founder, Chief Scientific Officer, Director
David J. Woodhouse
Chief Financial Officer
Alex M. DePaoli
Vice President - Clinical Research
Wenyan Shen
Vice President - Biologics
Hui Tian
Vice President - Research
Trombley Wun
Vice President - Business Development
Business Overview
NGM Biopharmaceuticals, a clinical-stage biopharmaceutical company developing novel therapeutics for the cardio-metabolic, liver, oncologic and ophthalmic diseases. The Company's product candidates include NGM282, NGM313, NGM386, NGM395, NGM120, NGM217 and NGM621. NGM282 is an engineered variant of the human hormone known as FGF19, which the Company is developing for the treatment of non-alcoholic steatohepatitis (NASH). NGM313 is an agonistic antibody selectively activating fibroblast growth factor receptor 1c-beta-klotho and has the potential as an insulin sensitizer for the treatment of type two diabetes and NASH. NGM386 and NGM395 are engineered variants of the human hormone known as GDF15, which is developed for the treatment of obesity. NGM120 is an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like, or GFRAL, that is designed to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome, and cancer.
Financial Overview
For the six months ended 30 June 2019, NGM Biopharmaceuticals Inc revenues increased 25% to $50.9M. Net loss increased from $7.1M to $15.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancin increase of 38% to $54.8M (expense), General and administrative - Balanci increase of 62% to $9M (expense).
Employees: 164 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $785.64M as of Jun 30, 2019
Annual revenue (TTM): $118.83M as of Jun 30, 2019
EBITDA (TTM): -$6.80M as of Jun 30, 2019
Net annual income (TTM): -$9.29M as of Jun 30, 2019
Free cash flow (TTM): -$21.78M as of Jun 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 66,042,966 as of Aug 9, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization